Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy.
This study investigates fasting serum levels of methionine and related metabolites, vitamin B6, and folate during highly active antiretroviral therapy in therapy-naive human immunodeficiency virus (HIV)-1-infected outpatients. The research design consisted of before and during therapy measurements with a median treatment period of 100 days (range, 50 to 188) in frozen samples. The subjects included 17 consecutive HIV-1-infected outpatients (15 men and 2 women; 25 to 65-years-old). Controls were 42 healthy individuals (28 men and 14 women; 24- to 82-years-old) without serologic evidence of HIV and/or hepatitis C infection and normal clinical chemistry. Subjects received treatment with the reverse transcriptase inhibitors, azidothymidine (AZT) or stavudine (D4T) plus lamivudine (3TC) and either the protease inhibitors, indinavir (IND), nelfinavir (NELF), ritonavir (RITV), or saquinavir (SAQ) at the standard dosage. Serum concentrations of methionine, total homocysteine (tHcy), cystathionine (CYSTA), N,N-dimethylglycine (DMG), N-methylglycine (MG), methylmalonic acid (MMA), and total cysteine, as well as vitamin B6, folate, and soluble tumor necrosis factor receptor p75 were taken at baseline and during highly active antiretroviral therapy. Baseline, serum tHcy, MMA, CYSTA, vitamin B6 concentrations were not significantly different from healthy controls. There was, however, a trend towards lower folate serum concentrations at baseline in HIV-infected patients as compared with healthy controls (P =.06). There were no significant correlations between tHcy and vitamin B6, folate, or MMA. Elevated baseline levels of DMG and MG decreased significantly during antiretroviral therapy (P =.0019 and.04, respectively), whereas no significant changes in serum concentrations of CYSTA, MMA, or methionine were detected. tHcy increased in 12 of 17 patients (P =.09). HIV-infected patients displayed significant alterations (elevated DMG and MG serum concentrations) in metabolite levels of the betaine pathway in methionine metabolism, which might be positively influenced by newly initiated antiretroviral combination therapy.
Look
M P
MP
Department of Internal Medicine I, University of Bonn, Bonn, Germany.
Riezler
R
R
Berthold
H K
HK
Stabler
S P
SP
Schliefer
K
K
Allen
R H
RH
Sauerbruch
T
T
Rockstroh
J K
JK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015703:Antigens, CD / Q000097:blood; D023241:Antiretroviral Therapy, Highly Active; D015415:Biomarkers / Q000097:blood; D003540:Cystathionine / Q000097:blood; D003545:Cysteine / Q000097:blood; D005215:Fasting; D005260:Female; D005492:Folic Acid / Q000097:blood; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy; D015497:HIV-1; D006710:Homocysteine / Q000097:blood; D006801:Humans; D008297:Male; D008715:Methionine / Q000097:blood; D008764:Methylmalonic Acid / Q000097:blood; D008875:Middle Aged; D015999:Multivariate Analysis; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood; D047889:Receptors, Tumor Necrosis Factor, Type II; D012521:Sarcosine / Q000031:analogs & derivatives* / Q000097:blood*; D025101:Vitamin B 6 / Q000097:blood
D019380:Anti-HIV Agents; D015703:Antigens, CD; D015415:Biomarkers; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D006710:Homocysteine; D003540:Cystathionine; C025138:dimethylglycine; D025101:Vitamin B 6; D008764:Methylmalonic Acid; D005492:Folic Acid; D008715:Methionine; D003545:Cysteine; D012521:Sarcosine